Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations

1 May 2019

Abstract excerpt

Abstract T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune-checkpoint inhibitor therapy or adoptive cell transfer. Much of the focus has been on identifying epitopes presented to CD8+ T cells by class I MHC. However, CD4+ class II MHC-restricted T cells have been shown to have an important role in antitumor immunity....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31043415
DOI: 10.1158/2326-6066.cir-18-0402

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver MutationsPMID 31043415Read ↗

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.Semantic proximity Read ↗

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine designSemantic proximity Read ↗

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular TherapySemantic proximity Read ↗

ImmuniT Platform for Improved Neoantigen Prediction in Lung CancerSemantic proximity Read ↗

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.Semantic proximity Read ↗

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.Semantic proximity Read ↗

Mutation-Derived Neoantigens for Cancer ImmunotherapySemantic proximity Read ↗

Harnessing neoantigen specific CD4 T cells for cancer immunotherapySemantic proximity Read ↗

Targeting neoantigens for cancer immunotherapy: Table 1.Semantic proximity Read ↗

Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and ProspectsSemantic proximity Read ↗

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.Semantic proximity Read ↗

Adoptive cell therapy targeting common p53 neoantigens in human solid cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.